This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Plaque Psoriasis

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Sponsored by Takeda

About this trial

Last updated 4 months ago

Study ID

TAK-279-3002

Status

Active, not recruiting

Type

Interventional

Phase

Phase 3

Placebo

Yes

Accepting

18-75 Years
18+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started 2 years ago

What is this trial about?

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 69 weeks.

What are the participation requirements?

Yes

Inclusion Criteria

Must be men and women of 18 years and older.
Must have a diagnosis of moderate-to-severe plaque psoriasis which hasn’t changed for at least 6 months.
Must be a candidate for light therapy (phototherapy) or therapy that treats the whole body (systemic therapy).
No

Exclusion Criteria

Cannot have a type of psoriasis that is not plaque psoriasis.
Cannot have previously taken TAK-279, deucravacitinib (a similar medicine), or apremilast.
Cannot have had a recent infection or have a history of certain infections.

Locations

Location

Status

For more information, view the full study details:

NCT06108544